Ken Griffin Ironwood Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 7,500 shares of IRWD stock, worth $32,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,500

Previous 3,800 97.37%

Holding current value

$32,850

Previous $24,000 25.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.93 - $7.04 $1.13 Million - $2.03 Million	287,893 Added 70.3%	697,426 $2.87 Million
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $2.36 Million - $3.65 Million	-423,741 Reduced 50.85%	409,533 $2.67 Million
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $2.81 Million - $5.22 Million	337,803 Added 68.18%	833,274 $7.26 Million
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $3.35 Million - $4.39 Million	381,454 Added 334.56%	495,471 $5.67 Million
Q3 2023 Nov 14, 2023	SELL	$8.25 - $11.35 $68,227 - $93,864	-8,270 Reduced 6.76%	114,017 $1.1 Million
Q2 2023 Aug 14, 2023	SELL	$10.1 - $11.6 $2.57 Million - $2.95 Million	-254,574 Reduced 67.55%	122,287 $1.3 Million
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $3.17 Million - $3.84 Million	305,687 Added 429.49%	376,861 $3.96 Million
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $521,284 - $654,501	52,655 Added 284.33%	71,174 $881,000
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $187,782 - $229,265	18,519 New	18,519 $192,000
Q2 2022 Aug 15, 2022	SELL	$11.05 - $12.72 $9.24 Million - $10.6 Million	-836,648 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.61 - $12.88 $5.14 Million - $6.24 Million	484,521 Added 137.6%	836,648 $10.5 Million
Q4 2021 Feb 14, 2022	BUY	$10.86 - $13.95 $2.83 Million - $3.63 Million	260,393 Added 283.86%	352,127 $4.11 Million
Q3 2021 Nov 15, 2021	SELL	$11.92 - $13.92 $950,035 - $1.11 Million	-79,701 Reduced 46.49%	91,734 $1.2 Million
Q2 2021 Aug 16, 2021	SELL	$10.16 - $13.11 $1.16 Million - $1.5 Million	-114,339 Reduced 40.01%	171,435 $2.21 Million
Q1 2021 May 17, 2021	SELL	$9.04 - $11.86 $612,631 - $803,740	-67,769 Reduced 19.17%	285,774 $3.2 Million
Q4 2020 Feb 16, 2021	SELL	$9.05 - $12.2 $2.57 Million - $3.47 Million	-284,403 Reduced 44.58%	353,543 $4.03 Million
Q3 2020 Nov 16, 2020	SELL	$8.99 - $10.74 $429,730 - $513,382	-47,801 Reduced 6.97%	637,946 $5.74 Million
Q2 2020 Aug 14, 2020	SELL	$9.14 - $11.97 $483,323 - $632,973	-52,880 Reduced 7.16%	685,747 $7.08 Million
Q1 2020 May 15, 2020	SELL	$8.58 - $14.01 $4.92 Million - $8.04 Million	-573,538 Reduced 43.71%	738,627 $7.45 Million
Q4 2019 Feb 14, 2020	SELL	$8.22 - $14.0 $10.4 Million - $17.7 Million	-1,266,004 Reduced 49.1%	1,312,165 $17.5 Million
Q3 2019 Nov 14, 2019	SELL	$8.59 - $10.96 $13.5 Million - $17.2 Million	-1,573,393 Reduced 37.9%	2,578,169 $22.1 Million
Q2 2019 Aug 14, 2019	BUY	$9.8 - $12.89 $8.01 Million - $10.5 Million	817,824 Added 24.53%	4,151,562 $45.4 Million
Q1 2019 May 15, 2019	BUY	$8.27 - $12.73 $15.2 Million - $23.4 Million	1,835,553 Added 122.52%	3,333,738 $0
Q4 2018 Feb 14, 2019	BUY	$7.8 - $16.13 $8.15 Million - $16.9 Million	1,044,652 Added 230.34%	1,498,185 $13 Million
Q3 2018 Nov 13, 2018	SELL	$14.31 - $17.65 $783,973 - $966,955	-54,785 Reduced 10.78%	453,533 $0
Q2 2018 Aug 10, 2018	BUY	$11.83 - $16.2 $3.11 Million - $4.26 Million	263,123 Added 107.31%	508,318 $0
Q1 2018 May 11, 2018	BUY	$11.13 - $13.63 $2.73 Million - $3.34 Million	245,195 New	245,195 $3.78 Million

Others Institutions Holding IRWD

# of Institutions

237

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $671M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account